DONATE TODAY
To Increase Patient Access

to Help People Feel Better and Live Longer

Download Brochure on the Benefits of Next Generation Sequencing (NGS) HERE.
The Endeavor Story
With advances in next-generation sequencing and molecular profiling, we now have the tools to uncover the genetic culprits of disease. We can go after targets and indications we were not scientifically capable of investigating in the past. And we can finally bring patients best-in-class medicines across a spectrum of indications that target the core drivers of disease – making a significant impact even in terminal conditions.

At Endeavor BioMedicines, they are pursuing novel science and developing precision medicines. They combine advancements in technology with insights into the causes of disease to develop best-in-class medicines with the potential to treat the most severe health conditions, including cancer and fibrosis.

The Future of Cancer Treatments

How Next Generation Sequencing can optimize treatment options for patients with solid tumors.

Featuring John Hood, CEO Endeavor Biomediomedicines with Dr. Jason Luke, UPMC and hosted by Montel Williams & Olga Villaverde.

Next Generation Sequencing

Potentially find your optimal treatment plan by identifying your specific cancer mutations through NGS testing. Every patient should get NGS testing done to understand what may be causing their cancer.
Discuss NGS testing with your healthcare provider to ensure that this is the right step for you.
This is a simple procedure that requires blood work or a tissue sample. A specialized lab analyzes these samples to fully sequence a large variety of mutations in your body. NGS testing is often encouraged in advanced cancer patients, and it represents a crucial step in delivering personalized medicines to patients.
Endeavor is partnered with xCures, a company that enables patients to find suitable treatment options. Endeavor is currently looking for patients with the PTCH1-Loss of Function (LOF) mutation. Regardless of your eligibility for the Endeavor Trial, xCures will send you a list of other treatment options that could work for your cancer mutation. This means that even if you do not qualify for the Endeavor trial, you will receive a list of other treatment options that could work against your cancer mutation.

Clinical Trials

Endeavor is developing ENV-101 for patients with tumor mutations in the Hedgehog pathway, which occur in approximately 2% of all cancers. Mutations in this pathway can aberrantly activate downstream signaling resulting in proliferation, survival, and metastasis of cancer cells. ENV-101 may potently inhibit the activity of the Hedgehog pathway, which may have a significant benefit on the lives of cancer patients with these mutations.

*Click the link below to read more at ClinicalTrials.gov.
Who Can Participate?

Any person 18 years of older.
Any person who has a PTCH-1 LOF mutation.
Any person who has an advanced solid tumor.

How can I help if I can't participate?
Spread the word. If you have a family member/friend who you think may qualify for this trial, reach out.
VIEW THE ENDEAVOR TRIAL BROCHURE

ENV-101

ENV-101 is a small molecule that potently inhibits the Hedgehog pathway. When abnormally activated, this pathway is associated with growth and progression of cancer. Normally, PTCH-1 keeps the Hedgehog pathway “off,” so when mutations occur in PTCH-1 that affect its function, the pathway can become highly activated and may become a key driver in those cancers.
Six clinical studies have characterized ENV-101, demonstrating that the molecule may be effective in some cancers and has a manageable safety profile.

Scan the QR code or click the button to learn more about ENV-101 for PTCH-1 LOF cancer treatment.
To see if you qualify for this clinical trial or for more information on how next generation sequencing can help provide access to additional treatment options, please contact by email, Gerrica Frankfurth, Manager of Patient Advocacy, at EBMClinical@endeavorbiomedicines.com. This email goes directly to her and then she triages each specific email/question, inquiry, etc. to the appropriate person at Endeavor BioMedicines or please call Gerrica directly at 858-537-1712.

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.
DONATE
envelopephone linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram